Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05618366
Other study ID # 22-04024678
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 7, 2023
Est. completion date December 2028

Study information

Verified date May 2024
Source Weill Medical College of Cornell University
Contact Tejasvi Kaur Sahni
Phone 646-962-8189
Email tks4001@med.cornell.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to learn about how a combination of tazemetostat and venetoclax in people with relapsed/refractory Non-Hodgkin Lymphoma (R/R NHL). The main questions that this trial aims to answer are what is the best dose of venetoclax to give with tazemetostat to people with R/R NHL; what types of side effects do people with R/R NHL get when taking venetoclax with tazemetostat; and what effects does this combination have on R/R NHL. Participants will need to take pills by mouth every day and regularly come to the clinic for blood work and imagining to monitor side effects and cancer progression. Participants may receive study drugs for up to 24 months.


Description:

This a phase 1, single arm, non-randomized trial of tazemetostat in combination with venetoclax in participants with two types of relapsed/refractory non-Hodgkin lymphoma. The purpose of this study is to evaluate the safety of the combination of tazemetostat and venetoclax in patients with relapsed/refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL). This trial will be conducted in two parts. Part one will be a single-arm, open-label sequential dose escalation (3+3) of venetoclax in combination with a fixed dose of tazemetostat (800mg BID) to determine the maximum tolerated dose (MTD) of venetoclax. In part two, two expansion cohorts (R/R DLBCL and R/R FL) will be enrolled to further characterize the safety and tolerability of the combination, and to estimate the preliminary efficacy. Up to 18 participants will be enrolled in part 1 and 20 participants will be enrolled in part 2.


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date December 2028
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed, biopsy-proven diagnosis of FL or DLBCL. - Subjects must have been treated with at least one prior line of therapy for lymphoma with evidence of disease progression. - Subjects are eligible if they have progressed after ASCT OR if they are ineligible for ASCT Exclusion Criteria: - Significant cardiovascular impairment, such as history of congestive heart failure, uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months of the first dose of study drug - Known hypersensitivity to any of the study drugs - History of other cancer (some exceptions apply) - Known CNS (brain or spinal cord) involvement at diagnosis - Richter's transformation from CLL - Evidence of uncontrolled systemic infection (viral, bacterial, or fungal) - Major surgery within 3 weeks prior to the start of study treatment - Venous thrombosis or pulmonary embolism within the last 3 months before starting study - Uncontrolled infection with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 - Pregnant or lactating (people capable of becoming pregnant or getting someone else pregnant must be willing to use highly effective birth control) - Malabsorption syndrome or other condition that precludes enteral route of administration - Inability to swallow tablets - Known allergy to both xanthine oxidase inhibitors and rasburicase - Clinically significant history of liver disease, including but not limited to viral or other hepatitis, current alcohol abuse, or cirrhosis - Active hepatitis C (defined as a positive HCV viral load) - Chronic use of moderate or strong CYP3A4 modulators (inhibitor or inducer); chronic use of a P-gp inhibitor, or a P-gp substrate with a narrow therapeutic index; or use of certain other prohibited medications - Prior exposure to either tazemetostat or venetoclax - Prior history of T-LBL/T-ALL - Previous solid organ transplant - Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin) - Vaccination with live vaccines within 28 days prior to treatment - Consumed grapefruit or grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study drug

Study Design


Intervention

Drug:
Venetoclax
Participants will receive oral venetoclax taken once per day. The dose will be between 200 and 800 mg daily, with the exact dose determined by the protocol.
Tazemetostat
Tazemetostat 800mg taken orally, twice daily.

Locations

Country Name City State
United States Weill Cornell Medicine/NewYork-Presberteryian Hospital New York New York

Sponsors (3)

Lead Sponsor Collaborator
Weill Medical College of Cornell University Epizyme, Inc., Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum-tolerated dose (MTD) determination (Part 1) In part 1 of this study, participants will be assigned a dose of venetoclax following a (3+3) dose escalation design and monitored for dose-limiting toxicities (DLTs) during the first treatment cycle. Based on observed DLTs observed in each dose level cohort, the maximum-tolerated dose will be determined. The # of patients experiencing a DLT among the evaluable patients for each dose level in part 1 will be tabulated. Day 0 to 28
Primary Number of participants who experience dose-limiting toxicities (DLTs) In part 1 of this study, participants will be assigned a dose of venetoclax following a (3+3) dose escalation design and monitored for dose-limiting toxicities (DLTs) during the first treatment cycle. Dose limiting toxicity (DLT) will be assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0). Day 0 to 28
Primary Number of participants who experience adverse events (AEs), from baseline to 30 days after the last dose of study drug, as assessed by CTCAE v5.0 The safety analysis population will consist of all enrolled patients who receive at least one dose of study drug. AEs and SAEs will be tabulated by type, grade, and attribution for all patients overall and by treatment group. For each patient, and within each type of toxicity, the patient will be counted only once at the highest grade of that toxicity. Participants will be evaluated for AEs/SAEs from the time they sign the informed consent form until 30 days after their last dose of study drug. Baseline through 25 months
Primary Number of adverse events (AEs) by severity from baseline to 30 days, after the last dose of study drug as assessed, by CTCAE v5.0 The safety analysis population will consist of all enrolled patients who receive at least one dose of study drug. AEs and SAEs will be tabulated by type, grade, and attribution for all patients overall and by treatment group. For each patient, and within each type of toxicity, the patient will be counted only once at the highest grade of that toxicity. Participants will be evaluated for AEs/SAEs from the time they sign the informed consent form until 30 days after their last dose of study drug. Baseline through 25 months
Secondary Number of Participants who Achieve Complete Response (CR) CR will be assessed for all evaluable patients in parts 1+2 according to Lugano response criteria. Day 0 through 24 months
Secondary Number of Participants who Achieve Partial Response (PR) PR will be assessed for all evaluable patients in parts 1+2 according to Lugano response criteria. Day 0 through 24 months
Secondary Overall Response Rate (ORR) The ORR response rate is the proportion of patients with a best overall response of either complete response (CR) or partial response (PR) among all evaluable patients. ORR, CR, and PR will be assessed for all evaluable patients in parts 1+2 according to Lugano response criteria. The best overall response is the best response recorded from the start of treatment until progressive disease. Day 0 through 24 months
Secondary Duration of Response (DoR) The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or PD is objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started).
The duration of overall CR is measured from the time measurement criteria are first met for CR until the first date that recurrent disease is objectively documented.
Duration of stable disease is measured from the start of the treatment until the criteria for progression are met, taking as reference the smallest measurements recorded since the treatment started.
From date of treatment initiation until the date of first documented progression or date of death from any cause, whichever came first, as assessed at 5 years
Secondary Progression-Free Survival PFS is defined as the duration of time from start of treatment to time of documentation of progression or death from any cause. From date of treatment initiation until the date of first documented progression or date of death from any cause, whichever came first, as assessed at 5 years
Secondary Overall Survival (OS) OS is defined as the duration of time from start of treatment to death from any cause. From date of treatment initiation until the date of death from any cause, as assessed at 5 years
Secondary Mean Change in Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Score from Baseline to End of Treatment FACT-Lym is a 42 item questionnaire that includes questions on physical well-being, social/family well-being, emotional well-being, functional well-being, and lymphoma symptoms over the past 7 days. Each response is measured on a 5 point Likert-type scale. Scores can range from 0 to 168 with higher scores indicating better quality of life. Baseline; at the start of Cycle 4 (a cycle is 28 days); at the start of Cycle 7; and End of Treatment (treatment will continue until disease progression or unacceptable toxicity for a maximum of approximately 2 years)
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT01804686 - A Long-term Extension Study of PCI-32765 (Ibrutinib) Phase 3
Completed NCT00001512 - Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines Phase 1
Recruiting NCT03676504 - Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR Phase 1/Phase 2
Active, not recruiting NCT03245021 - Nivolumab Plus Rituximab in First-line Follicular Lymphoma gr 1-3A Phase 1
Active, not recruiting NCT03078855 - A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma Phase 3
Recruiting NCT05365659 - IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas Phase 1
Active, not recruiting NCT04082936 - A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT02213263 - A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) Phase 3
Completed NCT01691898 - A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) Phase 1/Phase 2
Terminated NCT03585725 - A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma Early Phase 1
Terminated NCT00772668 - Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL N/A
Recruiting NCT02892695 - PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma Phase 1/Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Terminated NCT02204982 - Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma Phase 3
Completed NCT02536664 - Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma Participants
Terminated NCT00850499 - Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab Phase 2
Terminated NCT00475332 - Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar Phase 2
Terminated NCT00136591 - A Phase 2 Study of Velcadeā„¢ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma Phase 2
Not yet recruiting NCT06068881 - A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation Phase 2
Completed NCT04034056 - Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)